DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.

Author(s): Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H

Affiliation(s): Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. giovanni.schifitto@ctcc.rochester.edu

Publication date & source: 2006-03-28, Neurology., 66(6):919-21. Epub 2006 Mar 1.

Publication type: Randomized Controlled Trial

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Page last updated: 2006-11-04

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017